Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1635 1674
This examiner grants 64% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 16649572 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND METHODS OF INDUCING EXON SKIPPING | Final Rejection | Avidity Biosciences, Inc. |
| 18431197 | METHODS AND COMPOSITIONS FOR MODULATING APPETITE AND INTAKE OF SODIUM | Non-Final OA | California Institute of Technology |
| 18280126 | METHODS OF MODULATING NEURONAL AND OLIGODENDROCYTE SURVIVAL | Non-Final OA | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY |
| 17563963 | COMPOSITIONS AND METHODS FOR IDENTIFYING AND INHIBITING A PAN-CANCER CELLULAR TRANSITION OF ADIPOSE-DERIVED STROMAL CELLS | Final Rejection | The Board of Regents of the University of Texas System |
| 18270915 | METHOD FOR DIAGNOSIS AND TREATMENT OF AUTISM SPECTRUM DISORDER ON BASIS OF ACTIVITY REGULATION MECHANISM OF DORMANT NEURAL STEM CELL | Non-Final OA | DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION |
| 18637183 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | Non-Final OA | ALNYLAM PHARMACEUTICALS, INC. |
| 18299220 | METHODS FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES USING TRANSTHYRETIN (TTR) iRNA COMPOSITIONS | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 18247314 | SNCA IRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING SNCA-ASSOCIATED NEURODEGENERATIVE DISEASES | Non-Final OA | Alnylam Pharmaceuticals, Inc |
| 18077271 | RNAi COMPOSITIONS AND METHODS OF USE THEREOF FOR DELIVERY BY INHALATION | Non-Final OA | Alnylam Pharmaceuticals, Inc. |
| 17794920 | COMPOSITIONS AND METHODS TO TREAT NEUROLOGICAL DISEASES | Non-Final OA | University of Southern California |
| 17289544 | THERAPEUTIC AGENT FOR ARTHRITIS | Final Rejection | OSAKA UNIVERSITY |
| 18256805 | REGULATORY ELEMENTS FOR SCHWANN CELL-SPECIFIC GENE EXPRESSION | Non-Final OA | Wisconsin Alumni Research Foundation |
| 17795867 | ANTISENSE OLIGONUCLEOTIDE OF ATN1 | Non-Final OA | NISSAN CHEMICAL CORPORATION |
| 16757590 | Use of Syncytin for Targeting Drug and Gene Delivery to Lung Tissue | Non-Final OA | Université d'Evry val d'Essonne |
| 18653869 | COMPOSITIONS AND METHODS OF ALLEVIATING RESISTANCE TO CHEMOTHERAPY | Final Rejection | CITY OF HOPE |
| 18305809 | METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF | Non-Final OA | ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS |
| 18179410 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF PCSK9 | Non-Final OA | Sirnaomics, Inc. |
| 17782611 | RNAi-BASED TARGETING COMPOUNDS AND USES THEREOF TO PREVENT ACQUIRED HEARING LOSS | Final Rejection | MUSC FOUNDATION FOR RESEARCH DEVELOPMENT |
| 18552318 | MICRORNA-27B INHIBITORS | Non-Final OA | NEUmiRNA Therapeutics Aps |
| 18029725 | SIRT1 INHIBITOR OR ANTAGONIST FOR USE IN PREVENTING AND/OR TREATING AN HPV INDUCED TUMOUR | Final Rejection | UNIVERSITA' DEGLI STUDI DEL PIEMONTE ORIENTALE "A. AVOGADRO" |
| 17998662 | COMPOSITION FOR PREVENTING OR TREATING OBESITY-RELATED DISEASE CONTAINING AMPHIREGULIN-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE STRUCTURE | Final Rejection | SIRNAGEN THERAPEUTICS CORPORATION |
| 17920752 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Final Rejection | Flagship Pioneering, Inc. |
| 17920769 | BIFUNCTIONAL MOLECULES AND METHODS OF USING THEREOF | Final Rejection | Flagship Pioneering, Inc. |
| 17611927 | Compositions and Methods for Reducing Perineural Invasion and Pain | Final Rejection | Silenseed Ltd. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy